Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial
VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial
INOVIO also continues to partner with QIAGEN to develop a pre-treatment predictive biomarker with the goal of identifying women expected to respond to VGX-3100
PR Newswire
PLYMOUTH MEETING, Pa., March 1, 2021